Hemoglobinopathy Market: Size & Forecast, 2016 - 2022

Hemoglobinopathy is a blood disorder with abnormal structure of hemoglobin and is one of the common inherited diseases. It causes almost all genetic disorders related to hemoglobin and is classified into two types; thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). The common Hemoglobinopathies include sickle-cell disease, hemoglobin C disease and thalassemia. People who inherit the only unusual hemoglobin gene either from their mother or father and are called as “Carriers”, those are healthy and do not have any inherited disorder. According to WHO, 5% of adults are carrier of hemoglobin condition, 2.9% are for thalassemia and 2.3% are for sickle cell globally this is the result of migrating population of different groups from different regions. It is also found out that worldwide about 1.1% couples are at risk of having children with hemoglobinopathy.

It has been observed in a survey that annually there are 332,000 cases of conceptions or births and iron deficiency in children due to poverty conditions are the crucial factors responsible for fueling this market. The countries with higher population face the problems of accessing healthcare facilities and also lack of awareness about counselling can affect the market negatively. Hemoglobin related problems can cause major health issues as malaria and anemia which can be treated if diagnosed at an early stage. Due to development in the healthcare sector there are cheap and simple ways to test for adults as well as new-born. There are counselling facilities being provided in the low income countries to spread awareness and promote prenatal diagnosis and reassure the birth of the child.

The hemoglobinopathy market can be classified on the basis of product type and distribution channel.

Based on the product type the hemoglobinopathy market can be sub-divided into following:

Diagnosis

Routine Red Blood Cell (RBC) count
Genetic Testing
Electrophoresis or Chromatography

Treatment

Antibiotic Prophylaxis
Hydroxyurea
Others

Based on the disease indication the hemoglobinopathy market can be sub-divided into following:

Sickle Cell Disease
Beta Thalassemia
Alpha Thalassemia

Based on the distribution channel the hemoglobinopathy market can be sub-divided into following:

Pharmacies
Hospitals
Diagnostic Laboratories

Hemoglobinopathy is most common genetic disorder and thus every year 300,000 to 400,000 babies are diagnosed with serious hemoglobin disorders and 90% of the birth of these occur in the low income countries. Therefore, newborn screening is done so that the babies can be diagnosed quickly and treated to avoid further complications. The market for hemoglobinopathy will be growing steadily in the developing countries. According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries and constitute amongst the 5% of population are carriers of its variation. The diagnosis and treatment for sickle cell disease (SCD) will account for the largest market share.

Request Brochure of this Report: http://www.persistencemarketresearch.com/samples/10007

Depending on geographic region, hemoglobinopathy Market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The largest market share for hemoglobinopathy is in the Asia and Africa regions as incidence of hemoglobinopathy is high in low income countries. The sickle cell disease is mostly found in North America and thus there is a significant market for the disease related diagnosis and treatment. The market will grow as there are major developments at early stages of testing and companies will drive this growth by product innovations and various clinical trials. The countries facing the major health problems should be made aware of the treatments and new born testing should be promoted by healthcare companies.

Request to view TOC: http://www.persistencemarketresearch.com/toc/10007

In the hemoglobinopathy market the major companies offering solutions are PerkinElmer Inc., Bio-Rad Laboratories, Inc., Cipla Limited, Alkem, Errant Gene Therapeutics and others.

About Us:
Persistence Market Research (PMR) is an innovative provider of market research reports and consulting services. The three PMR pillars of strength that have helped us win clients for years are: Quality Research, Quick Research, and In-depth Research.

PMR’s team of seasoned analysts and consultants are experts in their domain. At PMR, we process complex, exhaustive primary and secondary research data into valuable insight. We Understand that each client has a unique problem statement, and address it with our strengths.

Contact:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: +1 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.